Alpha Tau Medical Ltd. (DRTS)
NasdaqCM · USD · Healthcare · Biotechnology
$12.89 (-2.05%) as of
Key statistics
- Market cap
- 1.19B
- Forward P/E
- -24.11
- EPS (TTM)
- -1.02
- Dividend yield
- 0.00%
- 52-week range
- 3.43 – 15.79
- Beta
- 1.22
- Profit margin
- 0.00%
- Analyst target
- $17.80
- Volume
- 379.00k
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Jerusalem, Israel
- Employees
- 121
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.